Vascular modulator therapeutic - Boehringer Ingelheim
Latest Information Update: 31 Mar 2023
At a glance
- Originator Boehringer Ingelheim
- Class Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Retinal disorders
Most Recent Events
- 16 Mar 2023 Vascular modulator therapeutic - Boehringer Ingelheim is available for licensing as of 16 Mar 2023. https://www.boehringer-ingelheim.com/human-pharma-clinical-pipeline
- 16 Mar 2023 Phase-I clinical trials in Retinal disorders in Germany, prior to March 2023 (Boehringer Ingelheim pipeline, March 2023)